Ireland’s Shire (SHPG) clinched Baxalta (BXLT) with a stock and cash offer worth $32 billion on Monday. The deal comes five months after the acquirer disclosed an unsuccessful takeover approach. The companies said Shire had agreed to offer the equivalent of $45.57 for each Baxalta share, including .1482 of a Shire share and $18 a share in cash. That’s 37.5 percent more than Baxalta’s closing price on Aug. 3 before news of Shire’s interest emerged. They said the fusion should allow the enlarged entity to increase sales in the double digits, and predicted it will have annual revenue of more than $20 billion by 2020. The deal reflects Shire CEO Flemming Ornshov’s push to expand the group’s rare disease portfolio. The Irish company in November clinched a $5.9 billion deal to buy another rare-disease specialist, Burlington, Mass.-based biotech company Dyax (DYAX) and said at the time, it could still afford to buy Baxalta. Shire said on Monday that it has secured at $18 billion bank loan to finance the purchase of the Deerfield, Ill.-based company, and will over time replace it with bonds. Baxalta was spun-off from Baxter International (BAX) in July, while Shire in October 2014 lost out on the $54 billion merger with AbbVie (ABBV) after its suitor balked at a clampdown on inversion deals.
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.